SelectScience
Join Free
Accelerating Science
NewsLife Sciences

Sartorius Stedim Biotech Partners with Nova Biomedical to Create a Unique Tool to for Automated Cell Culture Analysis

Sartorius Group
16 May 2017
Lois Manton-O'Byrne, PhD
Executive Editor

Product news

Sartorius Stedim Biotech (SSB), a leading international supplier to the biopharmaceutical industry, today announced an agreement with Nova Biomedical (Nova), a well-known US manufacturer of cell culture analyzers, to integrate their BioProfile® FLEX2 into the ambr® multi-parallel bioreactor systems for automated, at-line cell culture analytics.

SSB and Nova are collaborating to combine two highly innovative technologies. Both the BioProfile® FLEX2 analyzer and the parallel bioprocessing functionality of the ambr® create a unique tool able to simultaneously run, sample and analyze a massive number of cell culture conditions during high-throughput cell line, media and process development by Design of Experiments (DoE). This will allow biopharmaceutical companies to develop well-characterized cell culture processes in less time while preventing the process development bottleneck being shifted to the analytical laboratory.

The partnership will deliver full integrated analytics for the ambr® 15 cell culture system in Q3 2017 and later in 2017 for the ambr® 250 high throughput. The ambr® platform mimics the characteristics of classical bioreactors at the microscale by allowing automated parallel processing of single-use bioreactors. Integrating ambr® and the BioProfile® FLEX2 will benefit users by allowing independent sampling, sample transfer, analysis and automated feedback control in each mini bioreactor.

Stefan Schlack, Senior Vice President Marketing and Product Management at SSB, said: "The combination of ambr® and Nova’s BioProfile® FLEX2 solution saves time by significantly increasing the amount of data that can be generated per run. Together with our Umetrics and BioPAT® MFCS software suites, this will offer a complete solution to generate and analyze the vast amounts of data required for a QbD approach to upstream bioprocess development.”

“We’re very excited about this collaboration”, said Nicholas Theodore, Senior Vice President of Global Sales for Nova Biomedical. “The combination of Nova’s expertise in automated cell culture analysis and Sartorius’ talent in delivering micro-scale smart reactors will yield tremendous benefits for the biotech industry. The integration of BioProfile® FLEX2 with the ambr® cell culture systems will result in accelerated commercialization of products and the ability to develop more products at lower cost, while ensuring the best quality of biotherapeutics for patients worldwide.”

Related products

Request Quote for All Products

ambr® 250

Sartorius Group

ambr® 250 is a new bioreactor system for parallel fermentation or cell culture using 100-250mL single-use bioreactors controlled by an automated liquid handling platform.The new system, developed with two major industrial partners, builds on the original ambr® microscale technology developed by TAP Biosystems (now part of Sartorius Stedim Biotech).

(3)

Links

Sartorius GroupCompany website

Tags

Cell / Tissue CultureCell culture or tissue culture is used to study the biology of cells or tissues and to isolate cellular products in an environment which can be manipulated and well defined. Accurately control your culture environment with bioreactors or culture incubators, bind your cells to a surface or together with an extracellular matrix. Distinguish cell types with differential media or proliferate cells with certain characteristics using selective media. Enrich your media with supplements such as growth factors, sera and vitamins. Find the best cell and tissue culture products, kits and equipment in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Biopharmaceutical AdvancesBiopharmaceutical advances follow the development of pharmaceuticals derived from biotechnology, also known as biotechnology medicines. Biopharmaceuticals may be produced from cell lines, plants, or microbial cells. Important considerations of biopharmaceutical use include application, cost, production process and purification.Bioprocessing / FermentationBioprocessing is the use of biological materials to perform commercial, scientific or medical research processes. Biological materials used include cells, enzymes and organisms. Usually bioprocessing requires a batch or continuous bioreactor such as a fermentor or cell culture system. The advantages of using a reactor include high productivity, easy configuration, adjustable values and automation.BioprocessingBioprocessing is the use of biological systems for the conversion of raw materials to desired products. This includes the research, development and manufacturing stages of production and can refer to food processing, small-molecule pharmaceutical manufacture, production of recombinant protein therapeutics, or the generation of renewable energy.BiopharmaceuticalsBiopharmaceuticals are proteins and other compounds (such as nucleic acids) produced by living organisms that have uses as therapeutics or for in vivo diagnostics. The most well known example of a biopharmaceutical product, and the first to be approved for therapeutic use, was recombinant human insulin.BiotherapeuticsBiotherapeutics are proteins and other compounds (such as nucleic acids) produced by living organisms that have uses as therapeutics or in <i>in vivo</i> diagnostics. The most well-known example of a biotherapeutic product, and the first to be approved for therapeutic use, was recombinant human insulin.

Related articles

Sartorius Stedim Biotech Partners with Nova Biomedical to Create a Unique Tool to for Automated Cell Culture Analysis